Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· November 7, 2025

Century Aluminum projects Q4 adjusted EBITDA of $170M-$180M while advancing Mt. Holly expansion

View original at seekingalpha.com
Century Aluminum projects Q4 adjusted EBITDA of $170M-$180M while advancing Mt…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Net sales for Q3 2025 were $632 million, a $4 million increase primarily due to higher realized Midwest premium, partially offset by lower shipments

    80% confidence
  • Jamalco weathered Hurricane Melissa catastrophic storm, protecting the refinery from any significant damage and most importantly, without suffering a single injury

    80% confidence
  • Mt. Holly restart total project spend should be somewhere in the neighborhood of $50 million, with the additional volume generating about $25 million in additional EBITDA per quarter

    80% confidence
  • Production has restarted at Jamalco refinery and full production is expected to resume within weeks with no material financial impact from the storm

    80% confidence
  • Adjusted EBITDA was $101 million for Q3 2025, mainly driven by the increased Midwest premium price

    80% confidence
  • There is a clear stated preference for buybacks as the most likely form of capital return once targets are reached

    80% confidence
  • Q4 anticipated increases in both LME and Midwest premiums will contribute approximately $65 million incremental EBITDA over Q3 levels

    80% confidence
  • Q3 2025 reported net income was $15 million or $0.15 per share, with adjusted net income of $58 million or $0.56 per share excluding exceptional items

    80% confidence
  • Insurance policy limits are high enough to cover both the property and business interruption costs of the Grundartangi outage up to and including the 11-12 month timeline

    80% confidence
  • Management maintains net debt target of $300 million, anticipating reaching this goal early in 2026

    80% confidence
  • The Supreme Court case does not affect Section 232 tariffs

    80% confidence
  • Mt. Holly restart is expected to begin in Q2 2026 and be completed by the end of June, with production ramping up throughout the second quarter

    80% confidence
  • At current realized prices, we expect Q4 adjusted EBITDA in the range of $170 million to $180 million

    80% confidence
  • Timeline for Grundartangi restart is dependent on how quickly replacement transformers can be manufactured, shipped and installed, with current estimates at 11 to 12 months

    80% confidence
  • We now expect that we will see an approximately $0.05 year-over-year increase across our 2026 billet sales, which should generate an additional $30 million of 2026 EBITDA

    80% confidence
  • Century Aluminum is exploring repairs to reduce Grundartangi downtime and expects insurance coverage for these losses

    80% confidence
  • Outstanding global market conditions exist with rising aluminum prices and persistently challenged supply side dynamics

    80% confidence
  • The company is not for sale. We are very excited about our prospects

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com